To Determine the Frequency of Biochemical Adverse Effects in Patients on Meglumine Antimoniate Treatment for Cutaneous Leishmaniasis. (2024). Medical Forum Monthly, 30(9). https://medicalforummonthly.com/index.php/mfm/article/view/3872